Summary
This Nature paper, authored by leading genetic epidemiologists, reviews the role of human genetics in drug target discovery and clinical development. The authors examine how genetic approaches—including genome-wide association studies and functional validation—can identify and prioritise therapeutic targets with stronger evidence of human relevance. As suggested by the title and journal scope, the paper likely argues that genetics-informed target selection improves clinical success rates and accelerates translation from discovery to approved therapeutics.
UK applicability
The findings are relevant to UK clinical research and pharmaceutical development policy, particularly for NHS precision medicine initiatives and UK Biobank-linked research. The methodology described may inform how UK regulatory bodies evaluate genetic evidence in licensing decisions.
Key measures
Genetic evidence strength, target validation pathways, clinical trial outcomes, drug development timelines
Outcomes reported
The study examined the application of human genetic approaches to identify and validate drug targets for clinical development. The work synthesised evidence on how genetic discovery platforms can bridge target identification and therapeutic translation.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.